Lyytinen J - Search Results

1

Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.

Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Pöyhönen M, Paetau A. Pasanen P, et al. Among authors: lyytinen j. Neurobiol Aging. 2014 Sep;35(9):2180.e1-5. doi: 10.1016/j.neurobiolaging.2014.03.024. Epub 2014 Mar 26. Neurobiol Aging. 2014. PMID: 24746362

2

SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population.

Pasanen P, Palin E, Pohjolan-Pirhonen R, Pöyhönen M, Rinne JO, Päivärinta M, Martikainen MH, Kaasinen V, Hietala M, Gardberg M, Saukkonen AM, Eerola-Rautio J, Kaakkola S, Lyytinen J, Tienari PJ, Paetau A, Suomalainen A, Myllykangas L. Pasanen P, et al. Among authors: lyytinen j. Neurobiol Aging. 2017 Feb;50:168.e5-168.e8. doi: 10.1016/j.neurobiolaging.2016.10.014. Epub 2016 Oct 19. Neurobiol Aging. 2017. PMID: 27838048

3

[Will the mystery of Parkinson's disease be resolved?].

Lyytinen J, Kaakkola S. Lyytinen J, et al. Duodecim. 2005;121(3):275-84. Duodecim. 2005. PMID: 15787285 Review. Finnish. No abstract available.

4

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H. Lyytinen J, et al. Mov Disord. 1997 Jul;12(4):497-505. doi: 10.1002/mds.870120404. Mov Disord. 1997. PMID: 9251066 Clinical Trial.

5

The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H. Lyytinen J, et al. Clin Neuropharmacol. 2001 Jan-Feb;24(1):50-7. doi: 10.1097/00002826-200101000-00009. Clin Neuropharmacol. 2001. PMID: 11290882 Clinical Trial.

6

Progressive Stroke-Like Symptoms in a Patient with Sporadic Creutzfeldt-Jakob Disease.

Lyytinen J, Sairanen T, Valanne L, Salmi T, Paetau A, Pekkonen E. Lyytinen J, et al. Case Rep Neurol. 2010 Mar 12;2(1):12-18. doi: 10.1159/000289177. Case Rep Neurol. 2010. PMID: 20689629 Free PMC article.

7

Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study.

Lyytinen J, Kaakkola S, Gordin A, Kultalahti E, Teräväinen H. Lyytinen J, et al. Parkinsonism Relat Disord. 2000 Oct 1;6(4):215-222. doi: 10.1016/s1353-8020(00)00012-2. Parkinsonism Relat Disord. 2000. PMID: 10900396

8

The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Gordin A, Kultalahti ER, Teräväinen H, Sovijärvi A. Lyytinen J, et al. Parkinsonism Relat Disord. 2002 Jun;8(5):349-55. doi: 10.1016/s1353-8020(01)00050-5. Parkinsonism Relat Disord. 2002. PMID: 15177064 Clinical Trial.

9

Magnetoencephalographic Abnormalities in Creutzfeldt-Jakob Disease: A Case Report.

Wilenius J, Mäkelä JP, Lyytinen J, Paetau A, Palomäki M, Pekkonen E. Wilenius J, et al. Among authors: lyytinen j. Case Rep Neurol. 2010 Oct 11;2(3):122-127. doi: 10.1159/000321349. Case Rep Neurol. 2010. PMID: 21113405 Free PMC article.

10

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J. Kuoppamäki M, et al. Among authors: lyytinen j. Eur J Clin Pharmacol. 2009 May;65(5):443-55. doi: 10.1007/s00228-009-0622-y. Epub 2009 Feb 20. Eur J Clin Pharmacol. 2009. PMID: 19229530 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page